Cargando…

PB2622: A PROSPECTIVE, OPEN-LABEL ONGOING STUDY OF SAFETY AND TREATMENT SATISFACTION IN ADULT IMMUNE THROMBOCYTOPENIA (ITP) SUBJECTS AFTER SWITCHING TO AVATROMBOPAG FROM ELTROMBOPAG OR ROMIPLOSTIM

Detalles Bibliográficos
Autores principales:	Kolodny, Scott, Vredenburg, Michael, Zhang, Jessica, Jamieson, Brian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428788/ http://dx.doi.org/10.1097/01.HS9.0000977176.66781.66

Ejemplares similares

Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2023)

Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study
por: Al‐Samkari, Hanny, et al.
Publicado: (2022)

PB2048: HEMATOLOGIC RECOVERY INDUCED BY AVATROMBOPAG IN SAA REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSIVE THERAPY COMBINED WITH ELTROMBOPAG
por: Liu, Xiaoqing, et al.
Publicado: (2023)

PB2637: OUR EXPERIENCE WITH AVATROMBOPAG TREATMENT IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
por: Cervinek, Libor
Publicado: (2023)

PB2623: AVATROMBOPAG FOR THE TREATMENT OF CHILDREN WITH PERSISTENT AND CHRONIC IMMUNE THROMBOCYTOPENIA
por: An, Qi, et al.
Publicado: (2023)

PB2041: COMPARISON OF ELTROMBOPAG AND AVATROMBOPAG IN THE TREATMENT OF REFRACTORY/RELAPSED APLASTIC ANEMIA, A SINGLE CENTER STUDY IN CHINA
por: Zhang, Zhuxin, et al.
Publicado: (2023)

PB2311: LOW-DOSE PREDNISON AND ELTROMBOPAG COMBINATION AS FRONTLINE TREATMENT IN NEWLY DIAGNOSED ITP PATIENTS
por: Liu, S.-Y., et al.
Publicado: (2022)

PB2479: ELTROMBOPAG, BUT NOT AVATROMBOPAG, REGULATES BONE MARROW MICROENVIRONMENT MIMICKING APLASTIC ANEMIA THROUGH DOWN-REGULATION OF FERROPTOSIS INHIBITOR
por: Ji, Jiang, et al.
Publicado: (2023)

PB2608: THE MANAGEMENT OF IMMUNE THROMBOCYTOPENIA (ITP) IN NORWAY IN THE REAL LIFE – ANALYSIS OF THE NOR-ITP REGISTRY
por: Ilicheva, Ekaterina, et al.
Publicado: (2023)

Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment
por: Bidika, Erjola, et al.
Publicado: (2020)

PB2612: UNITED KINGDOM RETROSPECTIVE OBSERVATIONAL STUDY OF ROMIPLOSTIM AND OTHER TREATMENTS IN EARLY IMMUNE THROMBOCYTOPENIA
por: Mcdonald, Vickie, et al.
Publicado: (2023)

Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study
por: Oladapo, Abiola, et al.
Publicado: (2023)

PB2625: VAYHIT2: A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VS PLACEBO IN ADDITION TO ELTROMBOPAG IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) WHO FAILED FIRST-LINE STEROID TREATMENT
por: Zaja, Francesco, et al.
Publicado: (2023)

PB2307: A MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ROMIPLOSTIM PLUS DEXAMETHASONE VS DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED PRIMARY IMMUNE THROMBOCYTOPENIA
por: Mingot Castellano, M. E., et al.
Publicado: (2022)

PB2468: A RETROSPECTIVE STUDY OF ELTROMBOPAG IN PATIENTS WITH THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: MA, Liangming, et al.
Publicado: (2023)

PB2619: THE IMPACT OF ITP-DIRECTED TREATMENT ON FATIGUE AMONG CHILDREN AND ADOLESCENTS WITH CHRONIC ITP: DATA FROM THE ITP NATURAL HISTORY STUDY REGISTRY
por: Diraimo, Jennifer, et al.
Publicado: (2023)

PB2316: EFFICACY AND SAFETY OF ELTROMBOPAG IN PEDIATRIC PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA AND ITS EFFECT ON CELLULAR IMMUNE FUNCTION
por: 吴, ?.
Publicado: (2022)

Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives
por: Tsykunova, Galina, et al.
Publicado: (2022)

Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry
por: Doobaree, Indraraj Umesh, et al.
Publicado: (2019)

Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
por: Tremblay, Gabriel, et al.
Publicado: (2018)

Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia
por: Patwardhan, Pallavi, et al.
Publicado: (2021)

Cost- Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease
por: Mladsi, Deirdre, et al.
Publicado: (2020)

Long-Term Use of the Thrombopoietin-Mimetic Romiplostim in Children With Severe Chronic Immune Thrombocytopenia (ITP)
por: Bussel, James B, et al.
Publicado: (2015)

PB2308: QUALITY OF LIFE AND CLINICAL OUTCOMES IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) DURING TREATMENT WITH ROMIPLOSTIM IN A REAL-WORLD SETTING
por: Ionova, T., et al.
Publicado: (2022)

Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia
por: Tremblay, Gabriel, et al.
Publicado: (2018)

PB2620: NIGHTTIME SYMPTOMS ARE ASSOCIATED WITH FATIGUE AMONG CHILDREN AND ADOLESCENTS WITH CHRONIC ITP: DATA FROM THE ITP NATURAL HISTORY STUDY REGISTRY
por: Diraimo, Jennifer, et al.
Publicado: (2023)

PB2425: EFFICACY AND SAFETY OF COMBINED THERAPY OF RECOMBINANT HUMAN THROMBOPOIETIN AND ELTROMBOPAG FOR TREATMENT OF PERSISTENT THROMBOCYTOPENIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pan, Pan, et al.
Publicado: (2023)

Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects
por: Jawa, Vibha, et al.
Publicado: (2010)

Is There a Role for Biweekly Romiplostim in the Management of Chronic Immune Thrombocytopenia (ITP)? A Report of Three Cases
por: Rooprai, Jasjit Kaur, et al.
Publicado: (2018)

PB2630: ASSESSEMENT OF THE MANAGEMENT OF ITP IN ADULTS IN AN INTERNAL MEDICINE DEPARTMENT IN ALGERIA
por: Imene, Semoud, et al.
Publicado: (2023)

Pharmacokinetic Evaluation of Eltrombopag in ITP Pediatric Patients
por: Dionisi, Marco, et al.
Publicado: (2021)

Romiplostim plus danazol as salvage treatment for eltrombopag refractory immune thrombocytopenia: a retrospective pilot study
por: Nam, Chang Hyun, et al.
Publicado: (2021)

Avatrombopag: A Review in Thrombocytopenia
por: Markham, Anthony
Publicado: (2021)

PB2610: EPIDEMIOLOGY AND TREATMENT OF ITP: A SINGLE CENTRE, REAL-WORLD EXPERIENCE
por: Patel, Priya, et al.
Publicado: (2023)

PB1949: ELTROMBOPAG IN CHINESE PATIENTS WITH REFRACTORY OR RELAPSED SEVERE APLASTIC ANEMIA: A NON-RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II STUDY ASSESSING THE SAFETY AND EFFICACY OF ELTROMBOPAG
por: Chang, H., et al.
Publicado: (2022)

Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies
por: Kuter, David J., et al.
Publicado: (2019)

PB2298: THE RELATIONSHIP BETWEEN PLATELET SPECIFIC ANTIBODIES AND THE SEVERITY OF NEWLY DIAGNOSED PEDIATRIC ITP
por: Dong, S.
Publicado: (2022)

PB2632: DILLEMAS AND CHALLENGES IN ITP TREATMENT OF A PATIENT WITH THROMBOTIC AND HEMORRHAGIC EVENTS DEVELOPMENT
por: Smiljanic, Mihailo, et al.
Publicado: (2023)

The Impact of Ethnicity on the Response to Eltrombopag in Patients With Immune Thrombocytopenia (ITP) in Qatar: A Single Institution Experience
por: Yassin, Mohamed A, et al.
Publicado: (2022)

Correction to: Avatrombopag: A Review in Thrombocytopenia
por: Markham, Anthony
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_56t5jppm4prrhoeooehe1gdk8b